dinutuximab

Ligand id: 7979

Name: dinutuximab

References
1. Ahmed M, Cheung NK. (2014)
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
FEBS Lett.588 (2): 288-97. [PMID:24295643]
2. Berois N, Osinaga E. (2014)
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.
Front Oncol4: 114. [PMID:24904828]
3. Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V et al.. (2013)
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
MAbs5 (5): 801-9. [PMID:23924804]
4. Loibner H, Mutschlechner O, Ladenstein R, Klier I. (2014)
Method for Treating a GD2 Positive Cancer.
Patent number: US20140170155. Assignee: Apeiron Biologics Ag. Priority date: 18/06/2012. Publication date: 19/06/2014.
5. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. (1987)
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
Cancer Res.47 (4): 1098-104. [PMID:3100030]
6. Soman G, Kallarakal AT, Michiel D, Yang X, Saptharish N, Jiang H, Giardina S, Gilly J, Mitra G. (2012)
Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.
MAbs4 (1): 84-100. [PMID:22327432]